Imipramine Pamoate

Nocturnal Enuresis (bedwetting), Bulimia Nervosa, Panic Disorder + 3 more

Treatment

20 Active Studies for Imipramine Pamoate

What is Imipramine Pamoate

Imipramine

The Generic name of this drug

Treatment Summary

Imipramine is a tricyclic antidepressant (TCA) used to treat depression. It works by blocking the reuptake of serotonin and norepinephrine, two neurotransmitters that regulate mood. It also blocks certain receptors in the body, which can lead to side effects such as sedation, low blood pressure, and blurred vision. Imipramine is also sometimes prescribed to treat conditions such as chronic pain, panic disorder, ADHD, and PTSD.

Tofranil

is the brand name

image of different drug pills on a surface

Imipramine Pamoate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tofranil

Imipramine

1959

103

Effectiveness

How Imipramine Pamoate Affects Patients

Imipramine is a type of antidepressant that helps to treat depression by increasing the levels of serotonin and norepinephrine, two chemicals in the brain that can affect mood. It is similar to other drugs such as amitriptyline and doxepin. When taken, imipramine can lead to changes in the brain such as increased production of nerve cells and reduced stress responses. It is believed that these changes, along with its effect on serotonin, are what make it an effective antidepressant. Additionally, it may cause a decrease in certain receptors in the brain that help to regulate adrenaline.

How Imipramine Pamoate works in the body

Imipramine helps treat depression by blocking the removal of two important neurotransmitters, norepinephrine and serotonin, from the spaces between neurons. This allows these two chemicals to stay in the spaces between neurons longer, stimulating the neurons and relieving symptoms of depression.

When to interrupt dosage

The recommended dosage of Imipramine Pamoate is contingent upon the diagnosed condition, such as Bedwetting, Bulimia Nervosa and Depression. The amount of dosage is dependent on the mode of administration (e.g. Tablet, sugar coated or Tablet, sugar coated - Oral), as indicated in the below table.

Condition

Dosage

Administration

Nocturnal Enuresis (bedwetting)

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Neuropathic Pain

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Panic Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Bulimia Nervosa

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Depression

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Attention Deficit Hyperactivity Disorder

10.0 mg, , 75.0 mg, 100.0 mg, 125.0 mg, 150.0 mg, 50.0 mg, 25.0 mg, 25.0 mg/mL

, Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, sugar coated, Tablet, sugar coated - Oral, Injection, solution, Intramuscular, Injection, solution - Intramuscular

Warnings

Imipramine Pamoate has two contraindications and should not be concomitantly administered when afflicted with any of the conditions in the table below.

Imipramine Pamoate Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Imipramine Pamoate.

Common Imipramine Pamoate Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Imipramine is combined with Aclidinium.

Alfuzosin

Major

Imipramine may increase the hypotensive activities of Alfuzosin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Imipramine.

Amoxapine

Major

Imipramine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Amoxapine.

Imipramine Pamoate Toxicity & Overdose Risk

Taking too much imipramine can cause dryness in the mouth and eyes, increased body temperature, constipation, difficulty urinating, tiredness, agitation, nightmares, confusion, decreased appetite, stomach pain, vomiting, and a strange taste in the mouth. In rare cases, it can lead to low blood cell counts and blood clotting problems. Infants born to mothers taking imipramine may experience heart problems, fussiness, breathing difficulty, muscle spasms, convulsions, and difficulty urinating. Taking it with other drugs that increase serotonin levels can cause serotonin syndrome. The LD50 for rats is 250mg/

image of a doctor in a lab doing drug, clinical research

Imipramine Pamoate Novel Uses: Which Conditions Have a Clinical Trial Featuring Imipramine Pamoate?

779 active clinical trials are currently assessing the potential of Imipramine Pamoate to provide relief from Attention Deficit Hyperactivity Disorder, Bulimia Nervosa and Depression.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

63 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Nocturnal Enuresis (bedwetting)

2 Actively Recruiting

Not Applicable

Depression

300 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Bulimia Nervosa

0 Actively Recruiting

Panic Disorder

13 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Imipramine Pamoate Reviews: What are patients saying about Imipramine Pamoate?

4.3

Patient Review

1/16/2014

Imipramine Pamoate for Depression

Imipramine has been extremely effective for me in treating my psychiatric problems. I've been taking it for most of my life, and the imipramine pamoate formulation seems to really help with side effects like tremor and dry mouth. The old tricyclic antidepressants have a similar effect to the newer SNRIs but are much cheaper, so Imipramine is a great option.

4.3

Patient Review

11/19/2013

Imipramine Pamoate for Depression

The side effects of this medication were really terrible and it made my symptoms worse. I was stressed, agitated, and felt strung-out all the time. I took it for off-label use for ADHD and it is by far the worst medication I have ever taken.

2

Patient Review

1/6/2011

Imipramine Pamoate for Depression

I took this medication for its side effect of causing sleep.

1

Patient Review

7/1/2013

Imipramine Pamoate for Attention Deficit Disorder with Hyperactivity

Imipramine has helped me a lot with my incontinence issues.

Patient Q&A Section about imipramine pamoate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is imipramine pamoate?

"Imipramine belongs to a class of antidepressants known as tricyclics. It treats depression by increasing the levels of certain chemicals in the brain that are necessary for mental balance."

Answered by AI

What is imipramine pamoate used for?

"This drug is given to people who are suffering from depression. It is thought to work by aiding in the regulation of moods, and may also help with sleep and appetite. It may also give the patient more energy to take part in daily activities. The drug imipramine pamoate is classified as a tricyclic antidepressant."

Answered by AI

What is the difference between Imipramine HCl and pamoate?

"Imipramine HCl is FDA approved for adults and adolescents with depression, as well as bedwetting in children. Imipramine pamoate is only approved to treat depression in adults ages 17 and up."

Answered by AI

Is imipramine used for anxiety?

"Imipramine is a drug that is used to treat depression, anxiety, and panic disorder. It belongs to a class of drugs called tricyclic antidepressants. It is often used to treat bedwetting in children, even though it is not clear how it prevents bedwetting."

Answered by AI

Clinical Trials for Imipramine Pamoate

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. We will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then they will participate in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Image of University of California San Diego in La Jolla, United States.

AI Chatbot for Postpartum Loneliness

18+
Female
La Jolla, CA

The goal of this clinical trial is to learn whether a postpartum chatbot powered by generative artificial intelligence (genAI) can help new mothers get better pelvic floor health information and feel less lonely after childbirth. The main questions this study aims to answer are: * Does using the chatbot improve postpartum pelvic floor health knowledge? * Does using the chatbot help reduce feelings of loneliness during the postpartum period? * Does using the chatbot impact pelvic floor symptoms? Researchers will compare standard postpartum care to standard care plus the chatbot. Participants will: Be assigned by chance (like flipping a coin) to standard postpartum care with or without access to the chatbot. If in the chatbot group, participants will receive education and support via the chatbot over a 4-week period. Both groups will complete questionnaires to measure their pelvic floor knowledge, pelvic floor symptoms, feelings of loneliness, depression, infant bonding, perceived social support, adverse childhood experiences, and peri-traumatic distress. The chatbot was created by urogynecology experts in collaboration with UC San Diego computer science and biomedical informatics researchers. The chatbot is designed to give new mothers personalized, evidence-based information and support in real time.

Waitlist Available
Has No Placebo

University of California San Diego

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials
Image of Virtual/ No Physical Facility in Palm City, United States.

Akashic Records Sessions for Mental Health

18+
All Sexes
Palm City, FL

The goal of this clinical study is to learn the impact of two Akashic Records sessions on mental health symptoms in adults. We want to see how sessions are linked to stress, anxiety, and depression, and to resilience (ability to bounce back) and feelings of connectedness (to self, community, and humanity). Main questions this study will answer are: After two sessions, what is the impact on stress, anxiety, and depression? After two sessions, what is the impact on resilience and connectedness? How do participants describe their experience of the sessions? After two sessions, what are participants' views of their problems (insight), emotional experiences (impact) and observable behaviors in their daily life? What participants will do: Complete online surveys about their mood at four points: before the first session, before the second session, after the second session, and again 2 months later. Surveys include: DASS-21 (Depression, Anxiety, and Stress Scale) CD-RISC-10 (Connor-Davidson Resilience Scale) WATTS (Connectedness Scale) A short demographic form and satisfaction survey Attend two individual Akashic Records sessions (50-90 minutes each) over private video platform with a licensed clinical social worker (principal investigator) The first 50 participants will also join a one-hour interview with open ended questions with a licensed clinical social worker (co-investigator) about one week after the second session to share their experience in their own words. Who can take part: Adults ages 18 and older who can read and consent in English and who have experienced stress, anxiety, or low mood in the past year. How the research will happen: Sessions are held by secure video call. Participants will also complete private online surveys before, during, and after the sessions. Some participants may be invited to share their experiences in a one-on-one interview. All information is kept private and names are removed before analysis. Risks and benefits: Talking about personal topics may bring up strong emotions. Licensed clinicians conduct sessions, offer support, and provide referrals if needed. Possible benefits include new insights, greater peace or meaning, and improved coping; benefits are not guaranteed. Why this matters: Many people seek spiritual or transpersonal support for emotional concerns. This pilot study will provide early evidence on whether Akashic Records sessions may be a helpful, low-risk option and will guide future research.

Waitlist Available
Has No Placebo

Virtual/ No Physical Facility

Candice S Rasa, LCSW

Image of University of California, Los Angeles in Los Angeles, United States.

Virtual Reality Reward Training for Depression

18+
All Sexes
Los Angeles, CA

The purpose of this study is to compare the effects of enhanced Virtual Reality-Reward Training (eVR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Enhanced VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences. The current study tests an enhanced version of this training using improved virtual reality technology. Target enrollment is 80 participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either enhanced Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study. A subset of 8 participants randomly assigned to VR-RT will complete fMRI scans and EMA surveys. The total length of participation is around 3 months.

Phase 2
Recruiting

University of California, Los Angeles

Have you considered Imipramine Pamoate clinical trials?

We made a collection of clinical trials featuring Imipramine Pamoate, we think they might fit your search criteria.
Go to Trials